Mangoceuticals, Inc. MGRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 61.43% | -22.88% | 63.64% | -40.67% | -11.91% |
| Total Depreciation and Amortization | 1.10% | -34.93% | 1,706.85% | -97.03% | 101.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.68% | 2,449.70% | -99.03% | 110.23% | 61.70% |
| Change in Net Operating Assets | 506.72% | -90.89% | 353.67% | -672.96% | -43.94% |
| Cash from Operations | 80.13% | -21.66% | 13.17% | 1.20% | 44.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 36.59% | -6.31% | 52.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 28.48% | 26.61% | -43.95% |
| Foreign Exchange rate Adjustments | -475.00% | 42.86% | -- | -100.00% | -97.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 104.12% | -230.51% | 164.29% | 1,452.24% | 37.64% |